GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » PS Ratio

Ocumension Therapeutics (HKSE:01477) PS Ratio : 16.60 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ocumension Therapeutics's share price is HK$6.89. Ocumension Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.42. Hence, Ocumension Therapeutics's PS Ratio for today is 16.60.

The historical rank and industry rank for Ocumension Therapeutics's PS Ratio or its related term are showing as below:

HKSE:01477' s PS Ratio Range Over the Past 10 Years
Min: 11.52   Med: 83.28   Max: 592.16
Current: 16.66

During the past 6 years, Ocumension Therapeutics's highest PS Ratio was 592.16. The lowest was 11.52. And the median was 83.28.

HKSE:01477's PS Ratio is ranked worse than
62.6% of 1000 companies
in the Biotechnology industry
Industry Median: 9.29 vs HKSE:01477: 16.66

Ocumension Therapeutics's Revenue per Sharefor the six months ended in Dec. 2023 was HK$0.24. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.42.

During the past 12 months, the average Revenue per Share Growth Rate of Ocumension Therapeutics was 47.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 101.10% per year.

During the past 6 years, Ocumension Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 101.10% per year. The lowest was 101.10% per year. And the median was 101.10% per year.

Back to Basics: PS Ratio


Ocumension Therapeutics PS Ratio Historical Data

The historical data trend for Ocumension Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics PS Ratio Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - 526.47 154.87 34.91 16.10

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 154.87 - 34.91 - 16.10

Competitive Comparison of Ocumension Therapeutics's PS Ratio

For the Biotechnology subindustry, Ocumension Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's PS Ratio falls into.



Ocumension Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ocumension Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=6.89/0.415
=16.60

Ocumension Therapeutics's Share Price of today is HK$6.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ocumension Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ocumension Therapeutics  (HKSE:01477) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ocumension Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumension Therapeutics (HKSE:01477) Business Description

Traded in Other Exchanges
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Executives
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Liu Ye 2101 Beneficial owner
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Chen Ziqing 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Boyu Capital Fund Iv, L.p 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd 2201 Interest of corporation controlled by you
Summer Iris Limited 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines